Copyright Reports & Markets. All rights reserved.

Global Anti-VEGT Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Anti-VEGT Drugs
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Anti-VEGT Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Tyrosine Kinase Inhibitors
    • 1.3.3 Monoclonal Antibodies
    • 1.3.4 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Anti-VEGT Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Oncology
    • 1.4.3 Ophthalmology
    • 1.4.4 Others
  • 1.5 Global Anti-VEGT Drugs Market Size & Forecast
    • 1.5.1 Global Anti-VEGT Drugs Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Anti-VEGT Drugs Sales Quantity (2018-2029)
    • 1.5.3 Global Anti-VEGT Drugs Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Genentech (Roche)
    • 2.1.1 Genentech (Roche) Details
    • 2.1.2 Genentech (Roche) Major Business
    • 2.1.3 Genentech (Roche) Anti-VEGT Drugs Product and Services
    • 2.1.4 Genentech (Roche) Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Genentech (Roche) Recent Developments/Updates
  • 2.2 Regeneron Pharmaceuticals
    • 2.2.1 Regeneron Pharmaceuticals Details
    • 2.2.2 Regeneron Pharmaceuticals Major Business
    • 2.2.3 Regeneron Pharmaceuticals Anti-VEGT Drugs Product and Services
    • 2.2.4 Regeneron Pharmaceuticals Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Regeneron Pharmaceuticals Recent Developments/Updates
  • 2.3 Novartis
    • 2.3.1 Novartis Details
    • 2.3.2 Novartis Major Business
    • 2.3.3 Novartis Anti-VEGT Drugs Product and Services
    • 2.3.4 Novartis Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Novartis Recent Developments/Updates
  • 2.4 AstraZeneca
    • 2.4.1 AstraZeneca Details
    • 2.4.2 AstraZeneca Major Business
    • 2.4.3 AstraZeneca Anti-VEGT Drugs Product and Services
    • 2.4.4 AstraZeneca Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 AstraZeneca Recent Developments/Updates
  • 2.5 Bayer
    • 2.5.1 Bayer Details
    • 2.5.2 Bayer Major Business
    • 2.5.3 Bayer Anti-VEGT Drugs Product and Services
    • 2.5.4 Bayer Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Bayer Recent Developments/Updates
  • 2.6 Abbott
    • 2.6.1 Abbott Details
    • 2.6.2 Abbott Major Business
    • 2.6.3 Abbott Anti-VEGT Drugs Product and Services
    • 2.6.4 Abbott Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Abbott Recent Developments/Updates
  • 2.7 Santen
    • 2.7.1 Santen Details
    • 2.7.2 Santen Major Business
    • 2.7.3 Santen Anti-VEGT Drugs Product and Services
    • 2.7.4 Santen Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Santen Recent Developments/Updates
  • 2.8 Pfizer
    • 2.8.1 Pfizer Details
    • 2.8.2 Pfizer Major Business
    • 2.8.3 Pfizer Anti-VEGT Drugs Product and Services
    • 2.8.4 Pfizer Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Pfizer Recent Developments/Updates
  • 2.9 Sanofi
    • 2.9.1 Sanofi Details
    • 2.9.2 Sanofi Major Business
    • 2.9.3 Sanofi Anti-VEGT Drugs Product and Services
    • 2.9.4 Sanofi Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Sanofi Recent Developments/Updates
  • 2.10 Bristol-Myers Squibb
    • 2.10.1 Bristol-Myers Squibb Details
    • 2.10.2 Bristol-Myers Squibb Major Business
    • 2.10.3 Bristol-Myers Squibb Anti-VEGT Drugs Product and Services
    • 2.10.4 Bristol-Myers Squibb Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Bristol-Myers Squibb Recent Developments/Updates
  • 2.11 GlaxoSmithKline
    • 2.11.1 GlaxoSmithKline Details
    • 2.11.2 GlaxoSmithKline Major Business
    • 2.11.3 GlaxoSmithKline Anti-VEGT Drugs Product and Services
    • 2.11.4 GlaxoSmithKline Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 GlaxoSmithKline Recent Developments/Updates
  • 2.12 Eli Lilly & Company
    • 2.12.1 Eli Lilly & Company Details
    • 2.12.2 Eli Lilly & Company Major Business
    • 2.12.3 Eli Lilly & Company Anti-VEGT Drugs Product and Services
    • 2.12.4 Eli Lilly & Company Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Eli Lilly & Company Recent Developments/Updates
  • 2.13 Chugai Pharma
    • 2.13.1 Chugai Pharma Details
    • 2.13.2 Chugai Pharma Major Business
    • 2.13.3 Chugai Pharma Anti-VEGT Drugs Product and Services
    • 2.13.4 Chugai Pharma Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Chugai Pharma Recent Developments/Updates
  • 2.14 Kanghong Pharmaceutical
    • 2.14.1 Kanghong Pharmaceutical Details
    • 2.14.2 Kanghong Pharmaceutical Major Business
    • 2.14.3 Kanghong Pharmaceutical Anti-VEGT Drugs Product and Services
    • 2.14.4 Kanghong Pharmaceutical Anti-VEGT Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Kanghong Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Anti-VEGT Drugs by Manufacturer

  • 3.1 Global Anti-VEGT Drugs Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Anti-VEGT Drugs Revenue by Manufacturer (2018-2023)
  • 3.3 Global Anti-VEGT Drugs Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Anti-VEGT Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Anti-VEGT Drugs Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Anti-VEGT Drugs Manufacturer Market Share in 2022
  • 3.5 Anti-VEGT Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 Anti-VEGT Drugs Market: Region Footprint
    • 3.5.2 Anti-VEGT Drugs Market: Company Product Type Footprint
    • 3.5.3 Anti-VEGT Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Anti-VEGT Drugs Market Size by Region
    • 4.1.1 Global Anti-VEGT Drugs Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Anti-VEGT Drugs Consumption Value by Region (2018-2029)
    • 4.1.3 Global Anti-VEGT Drugs Average Price by Region (2018-2029)
  • 4.2 North America Anti-VEGT Drugs Consumption Value (2018-2029)
  • 4.3 Europe Anti-VEGT Drugs Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Anti-VEGT Drugs Consumption Value (2018-2029)
  • 4.5 South America Anti-VEGT Drugs Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Anti-VEGT Drugs Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Anti-VEGT Drugs Sales Quantity by Type (2018-2029)
  • 5.2 Global Anti-VEGT Drugs Consumption Value by Type (2018-2029)
  • 5.3 Global Anti-VEGT Drugs Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Anti-VEGT Drugs Sales Quantity by Application (2018-2029)
  • 6.2 Global Anti-VEGT Drugs Consumption Value by Application (2018-2029)
  • 6.3 Global Anti-VEGT Drugs Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Anti-VEGT Drugs Sales Quantity by Type (2018-2029)
  • 7.2 North America Anti-VEGT Drugs Sales Quantity by Application (2018-2029)
  • 7.3 North America Anti-VEGT Drugs Market Size by Country
    • 7.3.1 North America Anti-VEGT Drugs Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Anti-VEGT Drugs Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Anti-VEGT Drugs Sales Quantity by Type (2018-2029)
  • 8.2 Europe Anti-VEGT Drugs Sales Quantity by Application (2018-2029)
  • 8.3 Europe Anti-VEGT Drugs Market Size by Country
    • 8.3.1 Europe Anti-VEGT Drugs Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Anti-VEGT Drugs Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Anti-VEGT Drugs Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Anti-VEGT Drugs Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Anti-VEGT Drugs Market Size by Region
    • 9.3.1 Asia-Pacific Anti-VEGT Drugs Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Anti-VEGT Drugs Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Anti-VEGT Drugs Sales Quantity by Type (2018-2029)
  • 10.2 South America Anti-VEGT Drugs Sales Quantity by Application (2018-2029)
  • 10.3 South America Anti-VEGT Drugs Market Size by Country
    • 10.3.1 South America Anti-VEGT Drugs Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Anti-VEGT Drugs Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Anti-VEGT Drugs Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Anti-VEGT Drugs Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Anti-VEGT Drugs Market Size by Country
    • 11.3.1 Middle East & Africa Anti-VEGT Drugs Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Anti-VEGT Drugs Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Anti-VEGT Drugs Market Drivers
  • 12.2 Anti-VEGT Drugs Market Restraints
  • 12.3 Anti-VEGT Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Anti-VEGT Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Anti-VEGT Drugs
  • 13.3 Anti-VEGT Drugs Production Process
  • 13.4 Anti-VEGT Drugs Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Anti-VEGT Drugs Typical Distributors
  • 14.3 Anti-VEGT Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Anti-VEGT Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
    Anti-VEGF (Vascular Endothelial Growth Factor) drugs are a class of medications used to treat various eye conditions, particularly those affecting the retina and blood vessels at the back of the eye. VEGF is a protein that promotes the growth of new blood vessels. In certain eye diseases, excessive VEGF can contribute to abnormal blood vessel growth and leakage, causing vision problems or loss.
    Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
    The Global Info Research report includes an overview of the development of the Anti-VEGT Drugs industry chain, the market status of Oncology (Tyrosine Kinase Inhibitors, Monoclonal Antibodies), Ophthalmology (Tyrosine Kinase Inhibitors, Monoclonal Antibodies), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Anti-VEGT Drugs.
    Regionally, the report analyzes the Anti-VEGT Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Anti-VEGT Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Anti-VEGT Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Anti-VEGT Drugs industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Tyrosine Kinase Inhibitors, Monoclonal Antibodies).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Anti-VEGT Drugs market.
    Regional Analysis: The report involves examining the Anti-VEGT Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Anti-VEGT Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Anti-VEGT Drugs:
    Company Analysis: Report covers individual Anti-VEGT Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Anti-VEGT Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oncology, Ophthalmology).
    Technology Analysis: Report covers specific technologies relevant to Anti-VEGT Drugs. It assesses the current state, advancements, and potential future developments in Anti-VEGT Drugs areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Anti-VEGT Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Anti-VEGT Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
    Market segment by Type
    Tyrosine Kinase Inhibitors
    Monoclonal Antibodies
    Others
    Market segment by Application
    Oncology
    Ophthalmology
    Others
    Major players covered
    Genentech (Roche)
    Regeneron Pharmaceuticals
    Novartis
    AstraZeneca
    Bayer
    Abbott
    Santen
    Pfizer
    Sanofi
    Bristol-Myers Squibb
    GlaxoSmithKline
    Eli Lilly & Company
    Chugai Pharma
    Kanghong Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Anti-VEGT Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Anti-VEGT Drugs, with price, sales, revenue and global market share of Anti-VEGT Drugs from 2018 to 2023.
    Chapter 3, the Anti-VEGT Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Anti-VEGT Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Anti-VEGT Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGT Drugs.
    Chapter 14 and 15, to describe Anti-VEGT Drugs sales channel, distributors, customers, research findings and conclusion.

    Buy now